Display options
Cite
Baskaran A, Summers D, Willing SL, et al. Sleep architecture in ziprasidone-treated bipolar depression: a pilot study. Ther Adv Psychopharmacol. 2013;3(3):139-49doi: 10.1177/2045125312467348.
Baskaran, A., Summers, D., Willing, S. L., Jokic, R., & Milev, R. (2013). Sleep architecture in ziprasidone-treated bipolar depression: a pilot study. Therapeutic advances in psychopharmacology, 3(3), 139-49. https://doi.org/10.1177/2045125312467348
Baskaran, Anusha, et al. "Sleep architecture in ziprasidone-treated bipolar depression: a pilot study." Therapeutic advances in psychopharmacology vol. 3,3 (2013): 139-49. doi: https://doi.org/10.1177/2045125312467348
Baskaran A, Summers D, Willing SL, Jokic R, Milev R. Sleep architecture in ziprasidone-treated bipolar depression: a pilot study. Ther Adv Psychopharmacol. 2013 Jun;3(3):139-49. doi: 10.1177/2045125312467348. PMID: 24167686; PMCID: PMC3805453.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Psychopharmacol. 2013 Jun;3(3):139-49. doi: 10.1177/2045125312467348.

Sleep architecture in ziprasidone-treated bipolar depression: a pilot study.

Therapeutic advances in psychopharmacology

Anusha Baskaran, Dave Summers, Stephanie Lm Willing, Ruzica Jokic, Roumen Milev

Affiliations

  1. Centre for Neuroscience Studies, Queen's University, Providence Care, Mental Health Services, Kingston, Ontario, Canada.

PMID: 24167686 PMCID: PMC3805453 DOI: 10.1177/2045125312467348

Abstract

OBJECTIVES: This study investigated the effect of ziprasidone augmentation therapy on sleep architecture in bipolar depression.

METHODS: We conducted a double-blind, randomized, placebo-controlled clinical pilot trial of ziprasidone versus placebo in Diagnostic and Statistical Manual of Mental Disorders, fourth edition bipolar disorder with current major depressive episode. The effects during acute (2-5 days) and continuation treatment (28-31 days) were measured. Main outcomes were sleep architecture variables including rapid eye movement sleep (REM) and slow wave sleep (SWS) measured by polysomnography. Secondary outcomes included subjective sleep quality measures and illness severity measures including the 17-item Hamilton Depression Rating Scale (HAMD-17), Montgomery Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAMA) and Clinical Global Illness Severity (CGI-S) scores.

RESULTS: The completer analysis comprised of 14 patients (ziprasidone, N = 8 and placebo, N = 6). Latency to REM, duration of SWS, duration of stage 2 sleep, total sleep time, onset to sleep latency, number of awakenings and overall sleep efficiency significantly improved in ziprasidone-treated participants over placebo. CGI-S and HAMA scores also significantly improved. No significant difference between treatment groups was seen on the HAMD-17, MADRS or in self-reported sleep quality. Increase in SWS duration significantly correlated with improvement in CGI-S, however, this finding did not withstand Bonferroni correction.

CONCLUSION: Adjunctive ziprasidone treatment alters sleep architecture in patients with bipolar depression, which may partially explain its mechanism of action and merits further investigation.

Keywords: Atypical antipsychotic; REM; SWS; bipolar depression; polysomnography; sleep architecture; ziprasidone

References

  1. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57 - PubMed
  2. Psychiatry Res. 1989 May;28(2):193-213 - PubMed
  3. Eur J Neurosci. 2009 May;29(9):1795-809 - PubMed
  4. J Affect Disord. 2009 Nov;118(1-3):205-8 - PubMed
  5. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62 - PubMed
  6. Int Rev Psychiatry. 2005 Aug;17(4):237-45 - PubMed
  7. J Clin Psychiatry. 2005 Oct;66(10):1254-69 - PubMed
  8. Science. 1975 Jul 4;189(4196):55-8 - PubMed
  9. Can J Psychiatry. 2006 Jul;51(8):523-30 - PubMed
  10. Sleep. 1991 Dec;14(6):540-5 - PubMed
  11. Neuropharmacology. 1994 Mar-Apr;33(3-4):467-71 - PubMed
  12. Arch Gen Psychiatry. 2003 Nov;60(11):1079-88 - PubMed
  13. Hum Psychopharmacol. 2000 Mar;15(2):113-135 - PubMed
  14. Biol Psychiatry. 1996 Mar 15;39(6):411-8 - PubMed
  15. Prog Brain Res. 2008;172:625-46 - PubMed
  16. Ann Rheum Dis. 1981 Feb;40(1):87-9 - PubMed
  17. Depress Anxiety. 2006;23(6):364-72 - PubMed
  18. J Clin Psychiatry. 2005 Apr;66(4):450-4 - PubMed
  19. J Clin Psychiatry. 2003 Feb;64(2):192-6 - PubMed
  20. Trends Neurosci. 2001 Dec;24(12):726-31 - PubMed
  21. Br J Psychiatry. 1978 Nov;133:429-35 - PubMed
  22. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13 - PubMed
  23. Curr Opin Psychiatry. 2006 May;19(3):288-93 - PubMed
  24. Br J Psychiatry. 1979 Apr;134:382-9 - PubMed
  25. Neuropsychiatr Dis Treat. 2010 Sep 07;6:501-8 - PubMed
  26. J Clin Psychiatry. 2005 Aug;66(8):989-96 - PubMed
  27. Drugs. 2002;62(8):1217-51 - PubMed
  28. Sleep. 1992 Apr;15(2):173-84 - PubMed
  29. Sleep. 1999 Aug 1;22(5):667-89 - PubMed
  30. J Child Adolesc Psychopharmacol. 2005 Aug;15(4):696-702 - PubMed
  31. Depress Anxiety. 2001;14(1):3-6 - PubMed
  32. Psychiatry Clin Neurosci. 2001 Jun;55(3):305-10 - PubMed
  33. Biol Psychiatry. 1995 Sep 15;38(6):391-403 - PubMed

Publication Types